Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer.
作者信息
Lim Jeong Uk, Kang Hye Seon
机构信息
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
出版信息
Transl Lung Cancer Res. 2021 Sep;10(9):3709-3712. doi: 10.21037/tlcr-21-764.
Abstract
摘要
相似文献
1
Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer.
Transl Lung Cancer Res. 2021 Sep;10(9):3709-3712. doi: 10.21037/tlcr-21-764.
2
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.
3
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer.
Transl Lung Cancer Res. 2021 Sep;10(9):3713-3736. doi: 10.21037/tlcr-21-634.
4
[Chinese expert consensus on perioperative treatment of locally advanced gastric cancer (2021 version)].
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Sep 25;24(9):741-748. doi: 10.3760/cma.j.cn.441530-20210831-00351.
5
Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With Immunotherapy.
Cancer J. 2020 Nov/Dec;26(6):548-554. doi: 10.1097/PPO.0000000000000485.
6
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
Clin Transl Oncol. 2020 May;22(5):759-771. doi: 10.1007/s12094-019-02191-y. Epub 2019 Jul 31.
7
Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer.
Onco Targets Ther. 2019 Oct 3;12:8151-8159. doi: 10.2147/OTT.S222412. eCollection 2019.
8
Emerging role of immunotherapy in locally advanced non-small cell lung cancer.
Clin Adv Hematol Oncol. 2020 Apr;18(4):212-217.
9
Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
Curr Oncol Rep. 2020 Mar 5;22(4):31. doi: 10.1007/s11912-020-0882-3.
10
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial.
Transl Lung Cancer Res. 2021 Dec;10(12):4322-4327. doi: 10.21037/tlcr-21-882.
引用本文的文献
1
Impact of preoperative chemotherapy on cutaneous wound healing in lung cancer patients: A meta-analysis.
Int Wound J. 2024 Apr;21(4):e14518. doi: 10.1111/iwj.14518. Epub 2023 Dec 20.
本文引用的文献
1
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
Mol Oncol. 2021 Nov;15(11):2910-2922. doi: 10.1002/1878-0261.13090. Epub 2021 Sep 25.
2
Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Curr Treat Options Oncol. 2021 Aug 23;22(10):91. doi: 10.1007/s11864-021-00885-6.
3
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA.
Future Oncol. 2021 Nov;17(31):4045-4055. doi: 10.2217/fon-2021-0549. Epub 2021 Jul 19.
4
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12.
5
Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer.
Front Oncol. 2021 May 24;11:608608. doi: 10.3389/fonc.2021.608608. eCollection 2021.
6
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).
Immunotherapy. 2021 Jun;13(9):727-734. doi: 10.2217/imt-2021-0019. Epub 2021 Apr 21.
7
Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.
Thorac Cancer. 2021 May;12(9):1469-1488. doi: 10.1111/1759-7714.13942. Epub 2021 Mar 30.
8
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Nat Med. 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. Epub 2021 Feb 18.
9
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7.
10
The efficiency of F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1209-1219. doi: 10.1007/s00259-020-04711-3. Epub 2020 Feb 11.
Zotero 插件